Published in Int J Radiat Oncol Biol Phys on July 01, 2002
Predicting outcomes in radiation oncology--multifactorial decision support systems. Nat Rev Clin Oncol (2012) 2.23
Tumor delineation: The weakest link in the search for accuracy in radiotherapy. J Med Phys (2008) 1.39
Delineation in thoracic oncology: a prospective study of the effect of training on contour variability and dosimetric consequences. Radiat Oncol (2011) 1.00
Volumetric CT-based segmentation of NSCLC using 3D-Slicer. Sci Rep (2013) 0.98
A semiautomatic CT-based ensemble segmentation of lung tumors: comparison with oncologists' delineations and with the surgical specimen. Radiother Oncol (2012) 0.96
Multi-institutional comparison of treatment planning using stereotactic ablative body radiotherapy for hepatocellular carcinoma - benchmark for a prospective multi-institutional study. Radiat Oncol (2013) 0.82
"Two are better than one": a pilot study of how radiologist and oncologists can collaborate in target volume definition. Cancer Imaging (2006) 0.78
Inter-rater reliability between musculoskeletal radiologists and orthopedic surgeons on computed tomography imaging features of spinal metastases. Curr Oncol (2011) 0.78
Uncertainties in target volume delineation in radiotherapy - are they relevant and what can we do about them? Radiol Oncol (2016) 0.76
Impact of PET - CT motion correction in minimizing the gross tumor volume in non-small cell lung cancer. Asia Ocean J Nucl Med Biol (2013) 0.75
Comparison of novel multi-level Otsu (MO-PET) and conventional PET segmentation methods for measuring FDG metabolic tumor volume in patients with soft tissue sarcoma. EJNMMI Phys (2017) 0.75
Variabilities of Magnetic Resonance Imaging-, Computed Tomography-, and Positron Emission Tomography-Computed Tomography-Based Tumor and Lymph Node Delineations for Lung Cancer Radiation Therapy Planning. Int J Radiat Oncol Biol Phys (2017) 0.75
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol (2003) 5.84
The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol (2007) 5.79
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol (2010) 4.39
Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol (2010) 4.34
Non-small-cell lung cancer. Lancet (2011) 3.45
Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol (2012) 3.24
The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol (2015) 2.95
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol (2005) 2.80
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer (2010) 2.73
Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus. Nature (2011) 2.59
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncol (2012) 2.19
Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol (2012) 2.15
Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol (2003) 2.14
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol (2010) 2.12
The psychosocial impact of prostate cancer on patients and their partners. Med J Aust (2006) 1.76
Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer (2006) 1.75
Should extrapulmonary small cell cancer be managed like small cell lung cancer? Cancer (2010) 1.70
Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J Thorac Oncol (2010) 1.64
Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med (2002) 1.62
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res (2013) 1.55
Tobacco attitudes, practices, and behaviors: a survey of dentists participating in managed care. Nicotine Tob Res (2005) 1.53
Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma (2003) 1.52
Squamoproliferative lesions arising in the setting of BRAF inhibition. Am J Dermatopathol (2012) 1.51
The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review. Leuk Lymphoma (2014) 1.47
Efficacy of low dose radiotherapy for primary orbital marginal zone lymphoma. Leuk Lymphoma (2012) 1.46
Implementation of a lung radiosurgery program: technical considerations and quality assurance in an Australian institution. J Med Imaging Radiat Oncol (2012) 1.44
Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose. Int J Radiat Oncol Biol Phys (2010) 1.42
PSA response signatures - a powerful new prognostic indicator after radiation for prostate cancer? Radiother Oncol (2008) 1.42
Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.42
Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia. Asia Pac J Clin Oncol (2010) 1.40
Genetic approaches to alcohol dependence. Br J Psychiatry (2004) 1.40
CNS listeriosis confused with leptomeningeal carcinomatosis in a patient with a malignant insulinoma. Am J Clin Oncol (2002) 1.38
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. J Thorac Oncol (2015) 1.34
Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res (2009) 1.32
Small noncoding differentially methylated copy-number variants, including lncRNA genes, cause a lethal lung developmental disorder. Genome Res (2012) 1.26
Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer (2005) 1.22
Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2009) 1.21
How genetically heterogeneous is Kabuki syndrome?: MLL2 testing in 116 patients, review and analyses of mutation and phenotypic spectrum. Eur J Hum Genet (2011) 1.20
Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial. Radiother Oncol (2008) 1.20
Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. Chest (2012) 1.18
Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev (2011) 1.16
Psychiatric comorbidity and gender differences of persons incarcerated for methamphetamine abuse in Taiwan. Psychiatry Clin Neurosci (2004) 1.16
Lung cancer: challenges and solutions for supportive care intervention research. Palliat Support Care (2008) 1.15
Unplanned versus planned discharges from in-patient alcohol detoxification: retrospective analysis of 470 first-episode admissions. Alcohol Alcohol (2002) 1.15
Genome-wide linkage analysis of a composite index of neuroticism and mood-related scales in extreme selected sibships. Hum Mol Genet (2004) 1.14
Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. Int J Radiat Oncol Biol Phys (2008) 1.14
Conformal brachytherapy planning for cervical cancer using transabdominal ultrasound. Int J Radiat Oncol Biol Phys (2009) 1.14
Online adaptive radiotherapy for muscle-invasive bladder cancer: results of a pilot study. Int J Radiat Oncol Biol Phys (2010) 1.13
The impact of time between staging PET/CT and definitive chemo-radiation on target volumes and survival in patients with non-small cell lung cancer. Radiother Oncol (2013) 1.13
Meta-analysis of the association of the Taq1A polymorphism with the risk of alcohol dependency: a HuGE gene-disease association review. Am J Epidemiol (2007) 1.13
A distinctive colour associated with high iodine content in malignant pleural effusion from metastatic papillary thyroid cancer: a case report. J Med Case Rep (2013) 1.12
Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: mature results of a prematurely closed randomized Trans-Tasman Radiation Oncology Group trial (TROG 98.05). Radiother Oncol (2006) 1.11
Clinical expression of Menkes disease in females with normal karyotype. Orphanet J Rare Dis (2012) 1.11
An epidemiological survey of alcohol use disorders in a Tibetan population. Psychiatry Res (2008) 1.11
Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. Am J Med Genet B Neuropsychiatr Genet (2005) 1.10
A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer (2004) 1.09
Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. Pathology (2012) 1.07
Withdrawal-associated increases and decreases in functional neural connectivity associated with altered emotional regulation in alcoholism. Neuropsychopharmacology (2012) 1.07
N2-N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders-results of Trans Tasman Radiation Oncology Group Study 98.02. Head Neck (2008) 1.05
Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins. Int J Radiat Oncol Biol Phys (2007) 1.04
Distribution of proliferating bone marrow in adult cancer patients determined using FLT-PET imaging. Int J Radiat Oncol Biol Phys (2010) 1.03
Validity of recall of tobacco use in two prospective cohorts. Am J Epidemiol (2010) 1.03
Efforts to reduce mortality to hydroelectric turbine-passed fish: locating and quantifying damaging shear stresses. Environ Manage (2006) 1.02
Impact of distracted driving on safety and traffic flow. Accid Anal Prev (2013) 1.01
A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer (2013) 1.00
Association analysis of the DRD4 and COMT genes in methamphetamine abuse. Am J Med Genet B Neuropsychiatr Genet (2004) 1.00
Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging (2005) 0.99
Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia. J Thorac Oncol (2009) 0.99
Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. Melanoma Res (2014) 0.97
A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial. Int J Radiat Oncol Biol Phys (2010) 0.97
Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer. Int J Radiat Oncol Biol Phys (2012) 0.97
Primary testicular lymphoma. Blood (2013) 0.97
Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. Int J Radiat Oncol Biol Phys (2002) 0.96
Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting. Int J Colorectal Dis (2007) 0.96
A randomised, double-blind, placebo-controlled trial of nightly sildenafil citrate to preserve erectile function after radiation treatment for prostate cancer. J Med Imaging Radiat Oncol (2012) 0.96
Estimation of tumor volume in cervical cancer by magnetic resonance imaging. Am J Clin Oncol (2003) 0.95
Ocular risks from orbital and periorbital radiation therapy: a critical review. Int J Radiat Oncol Biol Phys (2011) 0.94
A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer (2009) 0.94
A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs (2006) 0.94
Reproducibility of "intelligent" contouring of gross tumor volume in non-small-cell lung cancer on PET/CT images using a standardized visual method. Int J Radiat Oncol Biol Phys (2010) 0.94
Mesenteric arteriographic findings in a patient with strongyloides stercoralis hyperinfection. J Vasc Interv Radiol (2002) 0.94
Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial. Clin Cancer Res (2011) 0.93
Variations in target volume definition for postoperative radiotherapy in stage III non-small-cell lung cancer: analysis of an international contouring study. Int J Radiat Oncol Biol Phys (2009) 0.93
Stage is not a reliable indicator of tumor volume in non-small cell lung cancer: a preliminary analysis of the Trans-Tasman Radiation Oncology Group 99-05 database. J Thorac Oncol (2006) 0.93